Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients

  • The FDA approved an expanded indication for Supernus Pharmaceuticals Inc's (NASDAQ:SUPN) Qelbree (viloxazine extended-release capsules) for attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older.
  • The FDA has now approved Qelbree for ADHD in children (starting at age 6), adolescents, and adults.
  • Qelbree is a novel non-stimulant taken once daily for full-day exposure. 
  • Related: Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights.
  • The approval is based on positive results from the Phase 3 study.
  • At a daily flexible-dose between 200mg to 600mg, the Phase 3 trial met the primary endpoint showing the reduction in the change from baseline of the Adult ADHD score was statistically significantly more significant in adults treated with Qelbree versus placebo.
  • Price Action: SUPN shares are up 3.58% at $28.90 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.